AVE - Avecho Biotechnology

[KIWIKARLOS]

Apparently the construction of the factory to make phosha E is basically finished with phase 2 trials starting now and a financial deal due to be finalised by end of this year. I think we are at basic support levels now its make or break for the company. If its a goer and i think the chances are very good there is potential for good profits next 3-6 months

 

[mrlawler46]

What does anyone think about Phosphagenics this time of year? In particular based on their new agreement with Metabolic. Also the announcement that 3 of their top brass have increased there holdings on 5th Oct 2009, one in particular by over 150%.

They have also said they will be going commercial with some of their products late 2009 early 2010.

Anyone have any thoughts?????

Matt

 

[dascore]

Hi friends,

Here is a chart update of POH in the Gann box-grid with a Volatility oscillator study together with the DTOscillator in the daily and weekly time frames.

We see some interesting signs of a soon coming rebound - however with the massive drops in the Dow recently, and esp. on last Friday where the Dow dropped over 320 points, let's watch and see how this will play out in time.


All the best!

Cheers

dascore

Disclaimer: I'm not an investment adviser. This post has been made solely for entertainment purposes and is not suitable for trading. Please DYOR. Position: Hold, Sentiment: Awaiting rebound

 

[bigdog]

POH PHOSPHAGENICS LTD

 

[greggles]

Phosphagenics up 15.79% to 2.2c today and currently at 12 month highs. No news, so I'm not sure what the catalyst behind today's share price increase is. Time will tell no doubt.

 

[bigdog]

greggles found this report today

http://hitechreporter.com/global-retinoic-acid-receptor-alpha-market-2018/39669/


August 25, 2018

Global Retinoic Acid Receptor Alpha Market 2018 – 3SBio Inc, Io Therapeutics Inc, Phosphagenics Ltd
By nicoleaustin on August 24, 2018

Global Retinoic Acid Receptor Alpha Market Report 2018 includes a total amalgamation of assessable trends and predicting analysis. This Retinoic Acid Receptor Alpha analysis offers an approach for a large number of clients. Employing accredited global Retinoic Acid Receptor Alpha market data resources together with various practices and tools to successfully get and study information, our accredited group of analysts, researchers, and advisors has obtained extra efforts in calling the global sector. The Retinoic Acid Receptor Alpha report suggests that the newest and also the very consistent statistics necessary for organizations in the global industry as a way to sustain in a competitive sector.

The report introduces the Retinoic Acid Receptor Alpha basics: definitions, categories, software and market review; product specifications; fabricating procedures; cost arrangements, development and so forth. Subsequently, it studied the international major Retinoic Acid Receptor Alpha industry market requirements, for example, merchandise price, profit, capacity, production, distribution, market and demand growth speed and prediction, etc. In the long run, the report introduced a new Retinoic Acid Receptor Alpha SWOT analysis, feasibility, and revenue investigation.

Key Manufacturers Analysis of Retinoic Acid Receptor Alpha Industry: 3SBio Inc, Io Therapeutics Inc, Phosphagenics Ltd, Sol-Gel Technologies Ltd

Retinoic Acid Receptor Alpha Report from Types, Application, along with Geography – International Forecast to 2023 is just indeed a skilled and comprehensive research study on the world’s major regional economy states, concentrating on the significant regions like Middle East and Africa, North America, Asia-Pacific, South America and Europe.

314

 

[bigdog]

Share price finished up 33% today at $0.024 (high of of $0.026)

ASX Announcement today
4/09/2018 2:56:32 PM 2 Phosphagenics Receives Arbitration Update from SIAC

ASX Limited
Market Announcements Office

Phosphagenics Receives Arbitration Update From SIAC

4 September 2018, Melbourne: Australian drug delivery company, Phosphagenics Limited (ASX: POH;
OTCQX: PPGNY) has this afternoon received an update from the Singapore International Arbitration
Centre (SIAC) as follows:

“The Tribunal [Arbitrator] has informed SIAC that we should expect the draft award shortly. We will continue to correspond with the Tribunal and update the Parties on the status of the draft award, as soon as we have further information.”

In previous correspondence, SIAC indicated that:

“Upon receipt of the Tribunal’s draft Award, we will of course, endeavour to expedite the scrutiny which typically takes at least three weeks, subject to the circumstances. Upon completion of the scrutiny, we will return the reviewed draft to the Tribunal for consideration and/or finalization.”

Neither SIAC nor the Tribunal have indicated when the parties may receive the Final Award.

Phosphagenics will continue to keep the market informed of further progress as required.

430

 

[bigdog]

Something is in play for POH

Volume for the past two days is in the millions
Shares Issued: 1,577 million
Value of trades today was $728,854
Market Cap Value $41 million
Share price increased $0.018 to $0.026 (with high of $0.029 today)

http://www.phosphagenics.com/wp-con...3b_phosphagenics_report_from_ndf_research.pdf

36 page report has been commissioned by Phosphagenics and prepard by NDF Research dated
Monday 23 July 2018

Page 1 includes para
In addition, it has significant potential for upside from an international arbitration with Mylan, expected to be decided soon. We value Phosphagenics at 5.6 cents per share base case and 11.7 cents optimistic case. Our target price of 9 cents sits at the midpoint of our valuation range. The current A$25.2 m market capitalisation, in addition to markedly undervaluing the replacement value of TPM ® , discounts the reasonable chance of commercial success for this company under its current leadership team

 

[HelloU]

has caught the eye of the day traders, and figures of 20cents per share being thrown about as a result of whatever this 'arbitration' thing is. I have done no research into this so take any figures in this post in that context....
What is this arbitration thing about?

 

[PZ99]

has caught the eye of the day traders, and figures of 20cents per share being thrown about as a result of whatever this 'arbitration' thing is. I have done no research into this so take any figures in this post in that context....
What is this arbitration thing about?

I think it's this... https://www.businesswire.com/news/home/20160106005744/en/Phosphagenics-Initiates-Arbitration-Mylan

 

[bigdog]

the important item is "Board recommends Return of Capital to shareholders from any net return of Mylan arbitration if successful"
http://www.phosphagenics.com/wp-content/uploads/2017/09/2017-Sept-01-Phosphagenics-Market-Update.pdf


ASX Limited Market Announcements Office
Phosphagenics Market Update
Board recommends Return of Capital to shareholders from any net return of Mylan arbitration
1 September 2017, Melbourne: Australian drug delivery company, Phosphagenics Limited (ASXOH; OTCQX: PPGNY), announced today that its Board of Directors has agreed that in the event Phosphagenics is successful in its ongoing arbitration withMylan and receives a material payment from Mylan, it will seek torecommend that a return of capital be made to shareholders of any cash proceeds received (after legal costs).

At present, the intention is that any potential quantum would be calculated using the following equation: 30% of net cash proceeds below AU$50M plus 50% of cash proceeds received between AU$50M and AU$100M plus 70% of cash proceed received above AU$100M. The proposal will be subject to shareholder approval after any award is announced and received.

In 2011/12Phosphagenics signed agreements with Agila Specialties Private Ltd to develop and market Phosphagenics’ TPM®/Daptomycininjectable.In 2013StridesShasun sold Agila Specialties Private Ltd, together with the agreements, to Mylan. Phosphagenics filed arbitration documents in 2016 asserting that both Agila and Mylan breached the agreements. Phosphagenics’ independent experts believe maximum total damages could approach US$300M. The arbitration hearing is to be conducted in Singapore in October/November 2017, with a decision anticipated in the first half of2018


http://www.phosphagenics.com/wp-con...enics-Initiates-Arbitration-Against-Mylan.pdf

6 January 2016, Melbourne: Australian biotechnology company, Phosphagenics Limited
(ASX: POH; OTCQX: PPGNY), announced today that it has commenced legal action
against Mylan Laboratories Limited (Mylan), a wholly-owned subsidiary of Mylan
Incorporated, by filing notices of arbitration at the Singapore International Arbitration
Centre.

Phosphagenics and Agila Specialties Private Limited (Agila) entered into a Master
Research Agreement (in 2011) and a Licensing Agreement (in 2012) to develop and
ultimately commercialise a formulation combining Phosphagenics’ proprietary TPM®
technology with the injectable antibiotic daptomycin, which is indicated for the treatment
of complicated skin and skin structure infections, andstaphylococcus aureus
bloodstream infections. In 2013 Mylan acquired Agila. A lead TPM®/Daptomycin
formulation is in the final stages of development by Mylan and, based on a patent filed
by Agila, is expected to have commercialadvantages over the existing formulation of
daptomycin. Daptomycin is currently marketed by Merck under the brand name Cubicin,
and is expected to have generic competition in the United States in June 2016.

The arbitration notices assert that Mylan is liable for breaches of several provisions under
the two relevant agreements, fraudulent or negligent misrepresentations, breaches of
confidence and/or unjust enrichment in relation to intellectual property and commercial
licensing terms, amongst others. The dispute has been referred to arbitration in
Singapore, in accordance with the relevant agreements. The substantive hearing is
expected to take place in late 2016. Meanwhile, the Licensing Agreement continues in
full force and effect pending the Arbitrator's decision.

Phosphagenics has already planned for the legal costs associated with the arbitration
proceedings in its 2016 budget. There is no assurance in respect of the outcome of the
arbitration proceedings and Phosphagenics will, in accordance with its continuous
disclosure obligations, notify the market of any material events as and when they occu

 

[bigdog]

UP 0.004 CENTS FOR MONTH

the important item is "Board recommends Return of Capital to shareholders from any net return of Mylan arbitration if successful"
http://www.phosphagenics.com/wp-content/uploads/2017/09/2017-Sept-01-Phosphagenics-Market-Update.pdf

ASX Limited Market Announcements Office
Phosphagenics Market Update
Board recommends Return of Capital to shareholders from any net return of Mylan arbitration
1 September 2017, Melbourne: Australian drug delivery company, Phosphagenics Limited (ASXOH; OTCQX: PPGNY), announced today that its Board of Directors has agreed that in the event Phosphagenics is successful in its ongoing arbitration withMylan and receives a material payment from Mylan, it will seek torecommend that a return of capital be made to shareholders of any cash proceeds received (after legal costs).

At present, the intention is that any potential quantum would be calculated using the following equation: 30% of net cash proceeds below AU$50M plus 50% of cash proceeds received between AU$50M and AU$100M plus 70% of cash proceed received above AU$100M. The proposal will be subject to shareholder approval after any award is announced and received.

In 2011/12Phosphagenics signed agreements with Agila Specialties Private Ltd to develop and market Phosphagenics’ TPM®/Daptomycininjectable.In 2013StridesShasun sold Agila Specialties Private Ltd, together with the agreements, to Mylan. Phosphagenics filed arbitration documents in 2016 asserting that both Agila and Mylan breached the agreements. Phosphagenics’ independent experts believe maximum total damages could approach US$300M. The arbitration hearing is to be conducted in Singapore in October/November 2017, with a decision anticipated in the first half of2018

 

[bigdog]

ASX announcement yesterday

Making progress with tribunal in Singapore

23/10/2018 9:11:11 AM Phosphagenics Receives Further Arbitration Process Update

 

[StanG]

POH shares may double or even triple or more within coming weeks. DYOR

 

[sval62]

POH shares may double or even triple or more within coming weeks. DYOR

This would have to be the post of the year.
Joe please give this man a prize or at least a one way ticket back to Hot Crapper

 

[HelloU]

ouch

 

[bigdog]

POH shares may double or even triple or more within coming weeks. DYOR

StanG -- looks like you got it wrong!!

Disappointing ASX announcement today no liked by market

The Board is very disappointed to announce that Phosphagenics was unsuccessful in all of its claims.

12/11/2018 8:31:45 AM 2 Phosphagenics Arbitration Award Issued

Phosphagenics – Arbitration Award Issued
12 November 2018, Melbourne: Australian drug delivery company, Phosphagenics Limited (ASX: POH; OTCQX: PPGNY), advises that the Singapore International Arbitration Centre (SIAC) issued its Partial Final Award at 12.24am on Saturday November 2018.

On 6 January 2016, Phosphagenics announced that it had commenced confidential arbitration proceedings against Mylan Laboratories Limited (Mylan), a wholly owned subsidiary of Mylan Incorporated, by filing notices of arbitration at the SIAC. In that announcement Phosphagenics advised that, in accordance with its continuous disclosure obligations, it would notify the market of any material events as and when they occur.

The Board is very disappointed to announce that Phosphagenics was unsuccessful in all of its claims.

The award includes findings against Phosphagenics’ claims to intellectual property rights relating to a lyophilised TPM®-daptomycin formulation; and its claim that Mylan had not used commercially reasonable efforts to develop TPM®-daptomycin.

Notwithstanding the award the Licensing Agreement remains in force. The Licencing Agreement includes clauses requiring Mylan to continue to take commerically reasonable efforts to develop TPM®-daptomycin, not to sell a generic daptomycin (with limited exceptions) and to pay royalties to Phosphagencis on commercial sales of TPM®-daptomycin. Phosphagenics may be required to enforce its remaining rights to require Mylan to act in line with requirements of the Licencing Agreement.

The parties will make submissions on costs (on a date to be set) which are reserved to a final award on costs. Phosphagenics has spent approximately $5.6m on arbitration and legal fees to date. The Board must take into account a significant adverse costs order.

As shareholders will recognize, this arbitration loss has a serious impact on the company and the Board will need to carefully consider the alternative courses of action available to it.
The company currently has cash on hand of $2.3m, which does not take account of a further $0.2m of R&D incentive refund expected before the end of the year.

 

[HelloU]

ouch

pre-trade heads up, down 90% 2day
once the chart can be drawn it is all too late.

 

[PZ99]

$2.3m in the bank and a "significant adverse costs order" pending.

Surprised they didn't go into a trading halt / suspension prior to this.

 

[Ann]

Darn...another falling knife! I wonder if there is going to be anyone out there trying to catch it? Ouch! As I said about FAR, maybe be better value elsewhere.